As in 2020, CRISPR still doesn't have an approved product -- but that could change soon. The stock has been volatile, providing investors with potential for both big gains and losses. But now that the ...

Vertex recently said the product may deliver more than $100 million in revenue in the 2025 full year. But it's important to ...

LabRoots invites you to the 3rd Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...

Genome editing technologies, such as CRISPR, are being applied to better understand basic biological systems as well as to research new kinds of gene and cell therapies. The CRISPR-Cas9 system ...

Rare genetic diseases are challenging for patients and their families—made all the more overwhelming because symptoms tend to appear soon after birth. To date, there haven’t been many reliable ...

The global prime editing and CRISPR market size was US$ 3,194.2 million in 2021. The global prime editing and CRISPR market is forecast to grow to US$ 17,618.4 million by 2030 by registering a ...

Growth stocks took off during 2020 amid the early stages of the pandemic. Buying during that time led to significant profits for some investors. One of the stocks that benefited from that bullishness ...